Specialty Magnets Assemblies,United States Magnets,Wholesale Magnetic Signs,Magnetic Specialities Inc Dongguan Zhenglong Magnet Co., Ltd , https://www.zlmagent.com
Shandong will cultivate 33 large-scale pharmaceutical companies
As the current global financial crisis has intensified, Shandong pharmaceutical companies have shown more and more momentum. The provincial pharmaceutical industry work conference held today revealed that by the end of 2010, our province will form 33 large-scale pharmaceutical enterprises with an annual sales income of more than RMB 1 billion.
The financial crisis has brought severe challenges to Shandong pharmaceutical companies, especially in the second half of the year. It is understood that in the first half of this year, the efficiency of pharmaceutical enterprises in the province increased by more than 50% year-on-year, but the year-on-year growth rate of industrial added value in the three months of 8, 9, and 10 dropped to 31.3%, 19.6%, and 10.1%, respectively, to about 10 points. The speed was declining month by month. “This crisis has a certain impact on the pharmaceutical industry, but from the increase in the value of the first 10 months of increase in value, profits and taxes, and technical reforms, the pharmaceutical industry is still significantly higher than the average level of the industry above the provincial scale.†The person in charge said.
The main economic indicators of the province's pharmaceutical industry rank among the top in the country, but there are only 4 enterprises with annual sales income of more than 2 billion yuan, and no one with more than 5 billion yuan, and no one pharmaceutical company has entered the top 100 industrial enterprises in the province, and domestic There is a certain gap between large-scale pharmaceutical groups in terms of scale and overall competitiveness. At the same time, the low proportion of high value-added products, inefficient self-innovation, and low-level competition in enterprises also restrict the development of the entire pharmaceutical industry. The financial crisis highlighted the scale issue.
A person in charge of the Provincial Economic and Trade Commission stated that “according to the current development trend, Qilu Pharmaceutical, Lunan Pharmaceutical, and Weigao Group's three companies are entirely likely to achieve sales revenue of over 10 billion within three years.â€
The situation shows that after years of savings, some large pharmaceutical companies in our province have entered the harvest season. According to the person in charge of Qilu Pharmaceutical, the company has achieved major developments in chemical synthetic raw material medicines and preparations, biotechnology medicines, fermentation raw material medicines, and animal vaccines. The sales revenue this year is nearly 4 billion yuan. The Weigao Group has already identified 34 key products and plans to build these products into products with a sales income of over 50 million yuan and over 100 million yuan within three to five years. The goal of the Weigao Group is not to be imagined. Last year, the company had more than 10 products with annual sales revenue of more than 50 million yuan, and the heart stent alone sold more than 100 million yuan.
The lack of innovative drugs is an important reason for the fact that our province's pharmaceutical industry is large but not strong and it is difficult to participate in international competition. The relevant person in charge of the Provincial Economic and Trade Commission believes that the fundamental way to solve this problem is to vigorously implement the science and technology promotion strategy, strengthen technological innovation and technological transformation, advance the advancement of pharmaceutical technology, increase the level of product research and development and technical equipment, and achieve independent innovation.
At present, the new base of Qilu Pharmaceutical has completed civil works, and the selection and purchase of new equipment are in progress. It is understood that this base is mainly used for the expansion of existing products and the construction of a mammalian cell expression system production line. Now, this company has 10 biotech drugs under study. Biotechnology drugs are only one of the key breakthrough drugs of pharmaceutical companies in our province, relying on advanced technologies such as information technology, new materials, and marine science and technology. Our enterprises are concentrating their advantages on the development of a number of new medicines. According to requirements, in the future, the pharmaceutical industry in our province will account for more than 5% of the sales revenue each year.
While promoting the development of large enterprises and accelerating product development, the province will also accelerate the development of pharmaceutical industry clusters and focus on the development of pharmaceutical industry parks in Zibo, Qingdao, Yantai, Jinan, and Heze.